Erasca Shareholders Face Securities Fraud Class Action Lawsuit
Investors who incurred financial losses from Erasca, Inc. stock between January 14, 2025, and April 26, 2026, are being invited to serve as lead plaintiffs in a newly filed securities fraud lawsuit. The litigation seeks to address alleged misrepresentations regarding the company’s internal drug development protocols.
The complaint, filed by the law firm Glancy Prongay Wolke & Rotter LLP, centers on the company’s ERAS-0015 pipeline asset. Plaintiffs allege that Erasca provided misleading assessments of its business operations by failing to disclose that preclinical data relied on improper comparisons to RevMed. These actions reportedly exposed the company to significant risks involving patent and trade secret infringement.
Investors wishing to participate in the class action or seek appointment as lead plaintiff must file their requests by August 10, 2026. Those who do not wish to take an active role in the litigation remain members of the class by default, though they retain the right to hire independent counsel. Further information regarding the case is available through the offices of Charles Linehan in Los Angeles.
Comments (0)
No comments yet. Be the first!